Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

ELI LILLY AND COMPANY

(LLY)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nyse
11/29/2021 11/30/2021 12/01/2021 12/02/2021 12/03/2021 Date
254.83(c) 248.04(c) 249.13(c) 247.88(c) 245.58(c) Last
4 041 677 8 265 918 3 241 515 3 817 784 4 125 045 Volume
-2.13% -2.66% +0.44% -0.50% -0.93% Change
More quotes
Estimated financial data (e) (USD)
Sales 2021 27 480 M - -
Net income 2021 6 130 M - -
Net Debt 2021 12 164 M - -
P/E ratio 2021 36,5x
Yield 2021 1,34%
Sales 2022 27 860 M - -
Net income 2022 7 001 M - -
Net Debt 2022 9 715 M - -
P/E ratio 2022 31,6x
Yield 2022 1,46%
Capitalization 223 B 223 B -
EV / Sales 2021 8,54x
EV / Sales 2022 8,34x
Nbr of Employees 35 000
Free-Float 99,8%
More Financials
Company
Eli Lilly and Company is a drug manufacturing company. The Company discover, develop, manufacture, and market products in a human pharmaceutical product segment. The CompanyÔÇÖs products include Diabetes and other endocrinology products, including Baqsimi, Basaglar, Forteo, Humalog, Humatrope, Humulin, Jardiance, Trajenta and Trulicity. Its Immunology products include Olumiant and Taltz. Its Neuroscience products... 
Sector
Pharmaceuticals
Calendar
12/12 | 09:30amPresentation
More about the company
Ratings of Eli Lilly and Company
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
B
More Ratings
All news about ELI LILLY AND COMPANY
12/03FDA adds strict safety warnings on arthritis drugs from Pfizer, AbbVie and Lilly
RE
12/03Eli Lilly, AbCellera Land FDA's Expanded Emergency Use Approval for COVID-19 Antibody T..
MT
12/03Eli Lilly Gets FDA's Expanded Emergency Use Approval for Antibody Therapy to Treat COVI..
MT
12/03FDA Expands Emergency Use for Lilly Antibody Combination for Covid-19 to Include Infant..
DJ
12/03Eli Lilly Sees FDA Granting EUA of Two Monoclonal Antibodies for Treatment of COVID in ..
MT
12/03AbCellera Biologics Names New Chief Commercial Officer
MT
12/03Eli Lilly, Innovent Biologics' Cancer Drug Added to China's Updated National Reimbursem..
MT
12/03Biotech Growth Stocks Set to Benefit from Rising Volatility (REGN, OTLC, AMGN, ILMN, LL..
AQ
12/02Innovent Biologics, Inc. and Eli Lilly and Company Announce Successful Expansion of Sin..
CI
12/02Special Report-U.S. rushed contracts to COVID-19 suppliers with troubled plants
RE
12/02What COVID-19 vaccine and drug makers have to say about Omicron
RE
12/01Lilly to Announce Initial 2022 Financial Guidance; Provide R&D Overview at Investment C..
PR
11/30US Stocks Slump as Omicron Variant, Fed Chief's Comment on Faster Asset Purchase Taperi..
MT
11/30CLOSE UPDATE : US Stocks See Sharp Decline as Omicron Variant, Fed Chief Comment on Faster..
MT
11/30Equities Drop Midday as Moderna CEO Questions COVID-19 Vaccines' Efficacy Against Omicr..
MT
More news
News in other languages on ELI LILLY AND COMPANY
12/03Eli Lilly et AbCellera obtiennent de la FDA l'autorisation d'utiliser en urgence le tra..
12/03Eli Lilly obtient de la FDA l'autorisation d'une utilisation d'urgence élargie pour une..
12/03AbCellera Biologics nomme un nouveau chef des affaires commerciales
12/03Le médicament anticancéreux d'Eli Lilly et Innovent Biologics ajouté à la liste actuali..
11/30Les actions américaines chutent en raison de la variante Omicron et du commentaire du c..
More news
Analyst Recommendations on ELI LILLY AND COMPANY
More recommendations
Chart ELI LILLY AND COMPANY
Duration : Period :
Eli Lilly and Company Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ELI LILLY AND COMPANY
Short TermMid-TermLong Term
TrendsBearishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 21
Last Close Price 245,58 $
Average target price 273,42 $
Spread / Average Target 11,3%
EPS Revisions
Managers and Directors
David A. Ricks Chairman, President & Chief Executive Officer
Anat Ashkenazi Chief Financial Officer & Senior Vice President
Timothy J. Garnett Chief Medical Officer & VP-Global Medical
Daniel M. Skovronsky Chief Scientific Officer & Senior Vice President
Diogo Rau Senior VP, Chief Information & Digital Officer
Sector and Competitors
1st jan.Capi. (M$)
ELI LILLY AND COMPANY47.55%222 641
JOHNSON & JOHNSON1.27%419 583
ROCHE HOLDING AG17.62%341 364
PFIZER, INC.44.09%304 610
NOVO NORDISK A/S64.51%244 010
ABBVIE INC.8.18%210 113